You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CAFCIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Cafcit patents expire, and what generic alternatives are available?

Cafcit is a drug marketed by Hikma and is included in one NDA.

The generic ingredient in CAFCIT is caffeine citrate. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the caffeine citrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cafcit

A generic version of CAFCIT was approved as caffeine citrate by EXELA PHARMA SCIENCE on September 21st, 2006.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CAFCIT?
  • What are the global sales for CAFCIT?
  • What is Average Wholesale Price for CAFCIT?
Drug patent expirations by year for CAFCIT
Drug Prices for CAFCIT

See drug prices for CAFCIT

Recent Clinical Trials for CAFCIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of ArkansasPhase 1
University of North Carolina, Chapel HillPhase 1
Thrasher Research FundPhase 1

See all CAFCIT clinical trials

Pharmacology for CAFCIT

US Patents and Regulatory Information for CAFCIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma CAFCIT caffeine citrate SOLUTION;INTRAVENOUS 020793-001 Sep 21, 1999 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma CAFCIT caffeine citrate SOLUTION;ORAL 020793-002 Apr 12, 2000 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for CAFCIT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Gennisium Pharma Gencebok caffeine citrate EMEA/H/C/005435
Treatment of primary apnoea of premature newborns.
Authorised no no no 2020-08-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.